Modeling Shear and Temperature Effects on protein structure in a High-Pressure Homogenizer: A CFD Approach

info:eu-repo/semantics/publishe

La psychopathologie phénoménologique

info:eu-repo/semantics/nonPublishe

Comparison between ZenoTOF 7600 system and QTOF for plant metabolome: an example of metabolomics applied to coffee leaves

info:eu-repo/semantics/inPres

Cross-Country Study on the Usage and Perception of Large Language Models (LLMs) in Teaching and Learning for Geotechnical Engineering.

info:eu-repo/semantics/publishe

Histoire et devenirs de l’eau à Bruxelles. Ce qu’une exposition met en perspective

info:eu-repo/semantics/inPres

Les Grands Petits Belges

"Les Grands Petits Belges" met en lumière les personnalités belges, célèbres ou oubliées, qui ont façonné notre pays. Raconté comme une histoire, chaque épisode se concentre sur une figure marquante de l'histoire de la Belgique, en se basant sur de la littérature existante, mais aussi sur de nouvelles archives peu ou pas explorées.Produit et diffusé par ULB Podcasts, ce projet invite le grand public à redécouvrir le riche patrimoine humain de la Belgique, souvent méconnu même de ses habitants.info:eu-repo/semantics/publishe

Ligand exchange in TREN-based Cobalt (II) funnel complexes in the solid state

info:eu-repo/semantics/publishe

Workflow4Metabolomics (W4M): A User-Friendly Metabolomics Platform for Analysis of Mass Spectrometry and Nuclear Magnetic Resonance Data.

Various spectrometric methods can be used to conduct metabolomics studies. Nuclear magnetic resonance (NMR) or mass spectrometry (MS) coupled with separation methods, such as liquid or gas chromatography (LC and GC, respectively), are the most commonly used techniques. Once the raw data have been obtained, the real challenge lies in the bioinformatics required to conduct: (i) data processing (including preprocessing, normalization, and quality control); (ii) statistical analysis for comparative studies (such as univariate and multivariate analyses, including PCA or PLS-DA/OPLS-DA); (iii) annotation of the metabolites of interest; and (iv) interpretation of the relationships between key metabolites and the relevant phenotypes or scientific questions to be addressed. Here, we will introduce and detail a stepwise protocol for use of the Workflow4Metabolomics platform (W4M), which provides user-friendly access to workflows for processing of LC-MS, GC-MS, and NMR data. Those modular and extensible workflows are composed of existing standalone components (e.g. XCMS and CAMERA packages) as well as a suite of complementary W4M-implemented modules. This tool suite is accessible worldwide through a web interface and is hosted on UseGalaxy France. The extensible Virtual Research Environment (VRE) provided offers pre-configured workflows for metabolomics communities (platforms, end users, etc.), as well as possibilities for sharing among users. By providing a consistent ecosystem of tools and workflows through Galaxy, W4M makes it possible to process MS and NMR data from hundreds of samples using an ordinary personal computer, after step-by-step workflow optimization. © 2025 Wiley Periodicals LLC. Basic Protocol 1: W4M account creation, working history preparation, and data upload Support Protocol 1: How to prepare an NMR zip file Support Protocol 2: How to convert MS data from proprietary format to open format Support Protocol 3: How to get help with W4M (IFB forum) and how to report a problem on the GitHub repository Basic Protocol 2: LC-MS data processing Alternate Protocol 1: GC-MS data processing Alternate Protocol 2: NMR data processing Basic Protocol 3: Statistical analysis Basic Protocol 4: Annotation of metabolites from LC-MS data Alternate Protocol 3: Annotation of metabolites from NMR data.info:eu-repo/semantics/publishe

Patrimoine(s) et nouvelles technologies :définitions, enjeux et perspectives

info:eu-repo/semantics/submittedForPublicatio

Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial

Background: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or higher in younger adults with risk factors than in healthy older adults in whom RSV vaccination is recommended. We conducted an immunobridging study using the Ad26/protein RSV preF vaccine, which previously demonstrated efficacy in adults aged ≥65 years to support extrapolation of efficacy demonstrated in an older population to younger adult populations at high risk of severe RSV disease. Methods: This Phase 3 randomized, double-blind, placebo-controlled trial assessed the safety/tolerability and immunogenicity of Ad26/protein preF RSV in adults aged 18–59 years without (Cohort 1) and with (Cohort 2) chronic cardiac or pulmonary comorbidities, compared to adults aged ≥65 years (Cohort 3) in whom efficacy against RSV disease was demonstrated. Humoral and cellular immune responses were assessed at baseline, Days 15 and 183. Reactogenicity and safety were assessed in all participants. Results: 1118 participants were enrolled (Cohort 1: 387; Cohort 2: 388; Cohort 3: 343). Compared to adults aged ≥65 years RSV neutralizing antibody titers were non-inferior in adults aged 18–59 years, including those at high risk. Levels of pre-F A IgG antibodies and frequencies of RSV-F specific interferon-gamma T-cells increased by Day 15 post-vaccination, and remained above baseline for at least 6 months in all cohorts. Reactogenicity and safety were clinically acceptable but age-dependent, with higher rates of Grade 3 systemic adverse events in adults aged 18–59-years than adults ≥65 years. Conclusion: Ad26/protein preF RSV vaccine induced robust humoral and cellular immune responses in adults aged 18–59 years with or without chronic cardiac or pulmonary comorbidities, of similar magnitude to responses in older adults, allowing inference of efficacy and protection against RSV-associated respiratory disease in this population. www.clinicaltrials.gov NCT05070546SCOPUS: ar.jinfo:eu-repo/semantics/publishe